Evaluating the effect of rapamycin treatment in Alzheimer’s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol

Evaluating the effect of rapamycin treatment in Alzheimer’s disease and aging using in vivo imaging: the ERAP phase IIa clinical study protocol

Background Rapamycin is an inhibitor of the mechanistic target of rapamycin (mTOR) protein kinase, and preclinical data demonstrate that it is a promising candidate for a general gero- and neuroprotective treatment in humans. Results from mouse models of Alzheimer’s disease have sho...

Full description

Bibliographic Details
Main Authors: Svensson, Jonas E., Bolin, Martin, Thor, Daniel, Williams, Pete A., Brautaset, Rune, Carlsson, Marcus, Sörensson, Peder, Marlevi, David, Spin-Neto, Rubens, Probst, Monika, Hagman, Göran, Morén, Anton Forsberg, Kivipelto, Miia, Plavén-Sigray, Pontus
Other Authors: Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Format: Article
Language:English
Published: Springer Science and Business Media LLC 2024
Subjects:
Neurology (clinical)
General Medicine
Online Access:https://hdl.handle.net/1721.1/154090

Internet

https://hdl.handle.net/1721.1/154090

Similar Items